WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
      Date of report (Date of earliest event reported): September 23, 2005

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

          Delaware                       000-14879                22-2322400
------------------------------   --------------------------  -------------------
 (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
       of Incorporation)                                     Identification No.)

  650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
-------------------------------------------------------------    ---------------
         (Address of Principal Executive Offices)                   (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200

          (Former Name or Former Address, if Changed Since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))


     On September 23, 2005, the Board of Directors of Cytogen  Corporation  (the
"Company")  adopted the 2005 Employee Stock Purchase Plan (the "2005 ESPP"). The
2005 ESPP will replace the Company's  existing  Employee  Stock  Purchase  Plan.
Under the 2005 ESPP eligible  employees may elect to purchase  shares of Cytogen
common  stock at 85% of the lower of fair  market  value as of the first or last
trading day of each participation  period.  Under the 2005 ESPP, officers of the
Company  who  purchase  shares may not  transfer  such shares for a period of 12
months  after the purchase  date.  The Company has  reserved  500,000  shares of
common stock for future  issuance  under the 2005 ESPP.  The Company  intends to
submit the 2005 ESPP for consideration by the stockholders of the Company at the
Company's Annual Meeting of Stockholders in 2006. No shares of common stock will
be  sold  pursuant  to the  2005  ESPP  unless  such  plan  is  approved  by the
stockholders of the Company.

     A copy of the ESPP, as adopted,  is attached hereto as Exhibit 10.1 to this
Current  Report on Form  8-K,  and is  incorporated  herein  by  reference.  The
foregoing description is qualified in its entirety by reference to such Exhibit.


(c) Exhibits.

        Exhibit No.       Description
        -----------       -----------

            10.1          Cytogen Corporation 2005 Employee Stock Purchase Plan.


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                             CYTOGEN CORPORATION

                                             By:   /s/ Michael D. Becker
                                                   Michael D. Becker
                                                   President and Chief Executive

Dated:   September 27, 2005

                                  EXHIBIT INDEX

        Exhibit No.       Description
        -----------       -----------

            10.1          Cytogen Corporation 2005 Employee Stock Purchase Plan.